AML Samples Show High Concordance in Detection of Mutations by NGS at Local Institutions versus Central Laboratories

By sjmartinez • July 18, 2023

Borate U, Yang F, Press RD, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick D, Juckett L, Norris BA, Bucy T, Burd A, Stein EM, Patel PA, Baer MR, Stock W, Schiller GJ, Blum W, Kovacsovics TJ, Litzow MR, Foran JM, Heerema NA, Rosenberg L, Marcus S, Yocum AO, Stefanos M, Druker BJ, Mims AS. AML Samples Show High Concordance in Detection of Mutations by NGS at Local Institutions versus Central Laboratories. Blood Adv. 2023 Jul 17:bloodadvances.2022009008. doi: 10.1182/bloodadvances.2022009008. Epub ahead of print. PMID: 37459200.

Tags: Hematology/Oncology, Publications

Related Posts

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CH, Sohn J, Lévy C, Jacot W, Tsurutani J, Roborel de Climens A, Wu X, Andrzejuk-Ćwik[...]

Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski[...]

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko[...]